Edition:
United Kingdom

Cleveland Biolabs Inc (CBLI.OQ)

CBLI.OQ on NASDAQ Stock Exchange Capital Market

1.50USD
16 Jul 2019
Change (% chg)

$0.01 (+0.67%)
Prev Close
$1.49
Open
$1.50
Day's High
$1.50
Day's Low
$1.50
Volume
325
Avg. Vol
4,061
52-wk High
$3.15
52-wk Low
$1.00

Latest Key Developments (Source: Significant Developments)

Cleveland Biolabs Q1 Loss Per Share $0.08 Excluding Items
Wednesday, 15 May 2019 

May 15 (Reuters) - Cleveland Biolabs Inc ::Q1 LOSS PER SHARE $0.08 EXCLUDING ITEMS.CLEVELAND BIOLABS-AS OF MARCH 31, 2019, HAD $3.3 MILLION IN CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS, IS EXPECTED TO FUND OPERATIONS INTO DEC 2019.REVENUE FOR Q1 OF 2019 DECREASED TO $0.20 MILLION COMPARED TO $0.23 MILLION FOR Q1 OF 2018.  Full Article

Cleveland Biolabs Inc QTRLY Loss Per Share $0.10
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - Cleveland Biolabs Inc ::CLEVELAND BIOLABS INC - QTRLY LOSS PER SHARE $0.10.  Full Article

Cleveland Biolabs Says Received Formal Notification From EMA
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Cleveland Biolabs Inc ::CLEVELAND BIOLABS - RECEIVED DAY 120 REVIEW QUESTIONS FROM EMA REGARDING MARKETING AUTHORIZATION APPLICATION FOR ENTOLIMOD.CLEVELAND BIOLABS - RECEIVED FORMAL NOTIFICATION FROM EMA THAT RESPONSES SHOULD BE SUBMITTED TO AGENCY BY SEPT 14.  Full Article

Cleveland Biolabs Reports Qtrly Loss Per Share $0.10‍​
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Cleveland Biolabs Inc ::CLEVELAND BIOLABS INC - QTRLY LOSS PER SHARE $0.10‍​.CLEVELAND BIOLABS-ESTIMATES CASH,CASH EQUIVALENTS,SHORT-TERM INVESTMENTS AS OF DEC 31 ENOUGH TO FUND OPERATIONS FOR AT LEAST 1 YEAR AFTER 10-K FILING DATE.  Full Article

Cleveland BioLabs reports Q3 ‍net loss per share, excluding minority interests, $0.11
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Cleveland BioLabs Inc :Cleveland BioLabs reports third quarter 2017 financial results and development progress.Q3 revenue $300,000 versus $1.1 million.Cleveland BioLabs Inc - qtrly ‍net loss, excluding minority interests, $0.11 per share​.Cleveland BioLabs -current cash,cash equivalents,short-term investments is expected to fund operations for at least 1 year beyond filing date of form 10-Q​.  Full Article

Cleveland BioLabs Q2 loss per share $0.50‍​
Monday, 14 Aug 2017 

Aug 14 (Reuters) - Cleveland BioLabs Inc :Cleveland BioLabs reports second quarter 2017 financial results and development progress.Q2 revenue $200,000 versus $600,000.Qtrly loss per share $0.50‍​.  Full Article